Carcinoma AdrenalNCT06279442
Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort
An observational study of Carcinoma Adrenal and Carcinoma, Adrenocortical Recurrent, run by Latin American Cooperative Oncology Group at 12 sites in Brazil.
Trial summary
This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma Adrenal, Carcinoma, Adrenocortical Recurrent
- How many people
- 150 participants
- Where
- 12 sitesBrazil
- Study dates
- 9 Oct 2024to 23 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Data will be included from 150 participants diagnosed with adrenocortical carcinoma who meet the study's inclusion and exclusion criteria. Data will be collected from the medical records of the included research sites throughout Brazil.
Who may be able to join
- Participants over 18 years old;
- Diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution;
- Initial diagnosis or recurrence from the year 2000 onwards.
Who cannot join
- Participants with insufficient clinical or pathological data in the medical records.
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
Brazil12 sites
Hospital de Amor de Barretos
Barretos, São Paulo, 14784-400
HUJBB - Hospital Universitário João de Barros Barreto da UFPA
Belém, Pará, 66073-000
UOPECCAN - Hospital do Câncer de Cascavel
Cascavel, Santa Catarina, 85.806-300
Hospital Erasto Gaertner
Curitiba, Paraná, 81.520-060
Pronutrir - Suporte Nutricional e Quimioterapia
Fortaleza, Ceará, 60.810-180
Hospital Santa Joana Recife (Instituto Américas PE)
Recife, Pernambuco, 52.011-000
INCA - Instituto Nacional de Câncer
Rio de Janeiro, Rio de Janeiro, 20.230-130
FUNFARME - Hospital de Base de São José do Rio Preto
São José do Rio Preto, São Paulo, 15.090-000
Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho
São Luís, Maranhão, 65.015-460
BP - A Beneficência Portuguesa de São Paulo
São Paulo, São Paulo, 01.323-030
HAOC - Hospital Alemão Oswaldo Cruz
São Paulo, São Paulo, 01.327-001
A.C. Camargo Cancer Center
São Paulo, São Paulo, 01.509-001
About this study
This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites.
Read the detailed description
Adrenocortical carcinoma is one of the rarest neoplasms in the world. In Brazil, especially in the South and Southeast regions, the incidence of adrenocortical tumors is around 15 times higher than in the rest of the world, largely attributed to the significant prevalence of the TP53-R337H germline mutation in this population. In view of this characteristic, the clinical and epidemiological characterization of this cohort, as well as the identification of prognostic factors, is of great importance. The starting point for this project was the cohort of 66 participants with adrenal carcinoma included in the final project of the medical residency in clinical oncology at the A.C. Camargo Cancer Center by student Rafael Haikal dos Santos Abduch. The aim is to include case studies from the main Brazilian site that have followed up and treated patients with adrenal carcinoma.
- Keywords
- Carcinoma adrenocortical
- Medical subject headings
- Adrenal Cortex Neoplasms, Carcinoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Demographic Characterization of Adrenocortical Carcinoma in Brazil
This measure aims to capture essential demographic attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include details such as age distribution in years, gender representation, geographic distribution, height in meters, weight in kilograms, as well as racial and ethnic demographics . These insights will contribute to a comprehensive understanding of the demographic landscape of adrenocortical carcinoma within the Brazilian population.
Measured: Throughout the study period, an average of 18 months.
Clinical Characterization of Adrenocortical Carcinoma in Brazil
This measure aims to capture essential clinical attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include relevant clinical factors such as tumor stage, hormone secretion status, and treatment modalities. These insights will contribute to a comprehensive understanding of the clinical landscape of adrenocortical carcinoma within the Brazilian population.
Measured: Throughout the study period, an average of 18 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2024
- Study start9 Oct 2024
- Primary completion23 Sep 2025
- Study completion23 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoma AdrenalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Latin American Cooperative Oncology Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Milena Shizue Tariki, Principal investigator, Latin American Cooperative Oncology Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06279442
- Sponsor's protocol ID
- LACOG 0723
- Status last verified
- Aug 2026
- First submitted
- 19 Feb 2024
- Last updated
- 2 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort
- ClinicalTrials.gov ID
- NCT06279442
- Acronym / sponsor ID
- LACOG 0723
- Keywords
- Carcinoma adrenocortical
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Latin American Cooperative Oncology GroupUniversity, hospital or other
- Study start
- 9 Oct 2024 (actual)
- Primary completion
- 23 Sep 2025 (actual)
- Study completion
- 23 Sep 2025 (actual)
- First posted
- 28 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites.
Detailed description
Adrenocortical carcinoma is one of the rarest neoplasms in the world. In Brazil, especially in the South and Southeast regions, the incidence of adrenocortical tumors is around 15 times higher than in the rest of the world, largely attributed to the significant prevalence of the TP53-R337H germline mutation in this population. In view of this characteristic, the clinical and epidemiological characterization of this cohort, as well as the identification of prognostic factors, is of great importance. The starting point for this project was the cohort of 66 participants with adrenal carcinoma included in the final project of the medical residency in clinical oncology at the A.C. Camargo Cancer Center by student Rafael Haikal dos Santos Abduch. The aim is to include case studies from the main Brazilian site that have followed up and treated patients with adrenal carcinoma.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Data will be included from 150 participants diagnosed with adrenocortical carcinoma who meet the study's inclusion and exclusion criteria. Data will be collected from the medical records of the included research sites throughout Brazil.
Key inclusion criteria (3 listed)
- Participants over 18 years old;
- Diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution;
- Initial diagnosis or recurrence from the year 2000 onwards.
Key exclusion criteria (1 listed)
- Participants with insufficient clinical or pathological data in the medical records.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Demographic Characterization of Adrenocortical Carcinoma in Brazil
Time frame: Throughout the study period, an average of 18 months.
This measure aims to capture essential demographic attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include details such as age distribution in years, gender representation, geographic distribution, height in meters, weight in kilograms, as well as racial and ethnic demographics . These insights will contribute to a comprehensive understanding of the demographic landscape of adrenocortical carcinoma within the Brazilian population.
Clinical Characterization of Adrenocortical Carcinoma in Brazil
Time frame: Throughout the study period, an average of 18 months.
This measure aims to capture essential clinical attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include relevant clinical factors such as tumor stage, hormone secretion status, and treatment modalities. These insights will contribute to a comprehensive understanding of the clinical landscape of adrenocortical carcinoma within the Brazilian population.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
Related trials for Carcinoma Adrenal
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruitingPhase 2
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Adrenocortical Carcinoma
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Milena Shizue Tariki principal investigator
Latin American Cooperative Oncology Group
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinoma Adrenal and Carcinoma, Adrenocortical Recurrent, run by Latin American Cooperative Oncology Group at 12 sites in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Demographic Characterization of Adrenocortical Carcinoma in Brazil (time frame: Throughout the study period, an average of 18 months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.